0 34

Korean Multicenter Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolic Agents for Nodular Hepatocellular Carcinomas: Six-Month Outcome Analysis

Authors
 Myungsu Lee  ;  Jin Wook Chung  ;  Kwang-Hun Lee  ;  Jong Yun Won  ;  Ho Jong Chun  ;  Han Chu Lee  ;  Jin Hyoung Kim  ;  In Joon Lee  ;  Saebeom Hur  ;  Hyo-Cheol Kim  ;  Yoon Jun Kim  ;  Gyoung Min Kim  ;  Seung-Moon Joo  ;  Jung Suk Oh 
Citation
 Journal of Vascular and Interventional Radiology, Vol.28(4) : 502-512, 2017 
Journal Title
 Journal of Vascular and Interventional Radiology 
ISSN
 1051-0443 
Issue Date
2017
MeSH
Adult ; Aged ; Aged, 80 and over ; Antibiotics, Antineoplastic/administration & dosage* ; Antibiotics, Antineoplastic/adverse effects ; Biliary Tract Diseases/etiology ; Carcinoma, Hepatocellular/mortality ; Carcinoma, Hepatocellular/pathology ; Carcinoma, Hepatocellular/therapy* ; Chemoembolization, Therapeutic*/adverse effects ; Chemoembolization, Therapeutic*/mortality ; Disease-Free Survival ; Doxorubicin/administration & dosage* ; Doxorubicin/adverse effects ; Drug Carriers* ; Female ; Humans ; Kaplan-Meier Estimate ; Liver Neoplasms/mortality ; Liver Neoplasms/pathology ; Liver Neoplasms/therapy* ; Male ; Middle Aged ; Neoplasm Staging ; Proportional Hazards Models ; Prospective Studies ; Registries ; Republic of Korea ; Time Factors ; Treatment Outcome ; Tumor Burden
Abstract
PURPOSE: To assess the efficacy and safety of transcatheter arterial chemoembolization with drug-eluting embolic (DEE) agents for nodular hepatocellular carcinoma (HCC). MATERIALS AND METHODS: The study design was a prospective multicenter registry-based, single-arm clinical trial that included 152 patients. One hundred three (67.8%) had a Child-Pugh class/score of A5, 114 (75.0%) had a performance status of 0, and 77 (50.7%) had Barcelona Clinic Liver Cancer (BCLC) stage A disease. The DEE chemoembolization procedures were performed with DC Bead particles loaded with doxorubicin solution. The primary endpoint of the study was 6-month tumor response assessed per modified Response Evaluation Criteria In Solid Tumors. Secondary endpoints were treatment safety and overall survival. RESULTS: At 1-month posttreatment assessment, complete response (CR) and objective response (OR; ie, CR or partial response) rates were 40.1% and 91.4%, respectively. At 6-month assessment, 121 patients remained for analysis, and CR and OR rates were 43.0% and 55.4%, respectively. The cumulative progression-free survival (PFS) rate at 6 months was 65.0%. Child-Pugh score, tumor multiplicity, and tumor size were independent predictors of PFS (P = .020, P = .029, and P = .001, respectively). There was no 30-day mortality. The overall 6-month survival rate was 97.4%. There were no grade 4 adverse events or laboratory changes. Serious adverse events were reported in 7.2% of patients, and persistent deterioration of liver function was observed in 3.9%. Prominent biliary injury was demonstrated in 19.7% of patients. No liver abscess was observed. CONCLUSIONS: DEE chemoembolization for nodular HCC had an acceptable safety profile and acceptable 6-month tumor response and survival rates.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/161148
Full Text
https://www.sciencedirect.com/science/article/pii/S1051044316305139
DOI
10.1016/j.jvir.2016.08.017
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실)
Yonsei Authors
김경민(Kim, Gyoung Min) ORCID logo https://orcid.org/0000-0001-6768-4396
이광훈(Lee, Kwang Hun)
주승문(Joo, Seung Moon)
Export
RIS (EndNote)
XLS (Excel)
XML
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse